ARKK Holdings of VERV
Verve Therapeutics
VERV, a biotechnology company, focuses on developing innovative gene-editing therapies aimed at treating cardiovascular diseases by targeting specific genetic causes. The company generates revenue primarily through research and collaboration agreements, licensing of its technology, and future commercialization of its therapeutic candidates.
Trades of VERV in ARKK
The ten most recent trades of Verve Therapeutics in the ARKK ETF.View all trades
Date | Direction | Market Value | % of Position | % of ETF |
|---|---|---|---|---|
| Jul 15, 2024 | Sell | $884 | 0.01% | 0.00% |
| Jul 12, 2024 | Sell | $14,802 | 0.20% | 0.00% |
| Jul 10, 2024 | Sell | $326,754 | 4.90% | 0.01% |
| Jul 09, 2024 | Sell | $391,220 | 5.73% | 0.01% |
| Jul 08, 2024 | Sell | $54,962 | 0.83% | 0.00% |
| Jul 05, 2024 | Sell | $331,692 | 5.35% | 0.01% |
| Jul 03, 2024 | Sell | $273,084 | 4.14% | 0.00% |
| Jul 02, 2024 | Sell | $524,907 | 8.01% | 0.01% |
| Jul 01, 2024 | Sell | $456 | 0.01% | 0.00% |
| Jun 25, 2024 | Sell | $36,813 | 0.49% | 0.00% |